Table 2.
Comparison of CD4 T cells count change between treatment groups and how other variables affect CD4 T cells reconstitution following the initiation of HAART.
| Comparison between baseline CD4 count and outcome after median of 5 months after HAART | ||||
| Group | Pretreatment cells/µL | Posttreatment cells/µL | p value | |
|
| ||||
| Overall | 142.5 ( 0–556) | 327 (45–972) | <0.0001 | |
| ZLE | 104 (0–509) | 200 (45–889) | <0.0001 | |
| TLE | 150 (3–556) | 337 (69–972) | <0.0001 | |
|
| ||||
| Determination of the effect HIV co-morbidities, gender, and increasing age on with CD4 T cell reconstitution | ||||
| Parameter | p value | |||
|
| ||||
| Gender | ||||
| CD4+ count change after 5 months of TLE/ZLE treatment | Male | Female | ||
| 149.7 (21–401) | 217 (7–516) | 0.0094 | ||
| Age group (years) | ||||
| 20 to 40 | >40 | |||
| 364.5 (45–972) | 352.1 (76–697) | 0.3184 | ||
| TB status | ||||
| No | Yes | |||
| 190.1 (0–500) | 211.9 (21–578) | 0.5717 | ||
| Hepatitis B status | ||||
| No | Yes | |||
| 172 (0–578) | 215.6 (52–319) | 0.3059 | ||
| Treatment group | ||||
| ZLE | TLE | |||
| 109.5 (21–275) | 214 (0–795) | <0.0001 | ||
|
| ||||
| Multivariate model to predict the influencing variables on CD4 change after HAART | ||||
| F (8, 78) = 1.03, Prob > F = 0.4176, R2 = 0.0959, adjusted R2 = 0.0032 | ||||
| CD4 change | Coefficient | Standard error | t | p value |
|
| ||||
| Gender | −89.999 | 47.207 | −1.91 | 0.060 |
| Age | −0.313 | 1.758 | −0.18 | 0.859 |
| Hepatitis B | 73.777 | 87.532 | 0.84 | 0.402 |
| Tuberculosis | 61.796 | 54.536 | 1.13 | 0.261 |
| Baseline CD4 | 0.066 | 0.1292 | 0.52 | 0.607 |
| Baseline Hb | 15.814 | 11.682 | 1.35 | 0.180 |
| Baseline CD8 | −0.0123 | 0.015 | −0.82 | 0.412 |
| Herbs use | −46.145 | 42.435 | −1.09 | 0.280 |
From the table, data is presented as median with range values. TLE: tenofovir, lamivudine, and efavirenz and ZLE: zidovudine, lamivudine, and efavirenz. p is significant at 0.05. Mann–Whitney test was used to compare the median CD4 cells count increase between the tenofovir treatment group (TLE) and the zidovudine treatment group (ZLE) and likewise the effect age, gender, and comorbidities at univariate level. The last part of the table is a multivariate regression analysis to identify variables that may predict CD4 T cells count change. t is the test-statistic, and p > t is the probability of predictive value of each variable on CD4 T cells count significant at 0.05. R2 measures the degree of correlation between variables with CD4 T cells count change.